ECM Therapeutics, Inc. — Form D/A

ECM Therapeutics, Inc. of WARRENDALE, PA, a company, filed a Form D amendment with the SEC on 2025-10-10. The offering totals $40.0M, of which $35.2M was reported sold. Industry: Biotechnology.

Offering

Filed: 2025-10-10
Form: D/A
Accession: 0001743104-25-000002
Industry: Biotechnology
Exemptions: 06b
Total offering: $40.0M
Amount sold: $35.2M
Remaining: $4.8M
Investors: 190
Date of first sale: 2018-05-28
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-314165

Issuer

Name: ECM Therapeutics, Inc.
CIK: 0001743104
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2017
Address: 118 MARSHALL DRIVE, WARRENDALE, PA, 15086
Phone: 724-242-7106

Officers, directors & promoters (10)

Name	Role	Location
Stephen F Badylak	Director	Warrendale, PA
Katie F Collins	Director	Warrendale, PA
PAUL F FAGAN	Director	WARRENDALE, PA
Stephen F Badylak	Executive Officer	Warrendale, PA
Katie F Collins	Executive Officer	Warrendale, PA
Jenna F Dziki	Executive Officer	Warrendale, PA
PAUL F FAGAN	Executive Officer	WARRENDALE, PA
George F Hussey	Executive Officer	Warrendale, PA
Lindsey F Saldin	Executive Officer	Warrendale, PA
Christine F Sheehy	Executive Officer	Warrendale, PA

Other filings by this issuer (7)

Filed	Form	Offering	Sold
2024-05-30	D/A	$30.0M	$26.1M
2023-06-09	D/A	$25.0M	$21.0M
2022-09-14	D/A	$20.0M	$15.9M
2021-07-30	D/A	$15.0M	$10.1M
2019-09-18	D/A	$10.0M	$6.5M
2019-06-18	D/A	$5.0M	$2.4M
2018-06-08	D	$5.0M	$919K

More